Skip to main content
$0.043 0.002 (4.88%)

High

$0.05

Low

$0.04

Trades

61

Turnover

$61,445

Volume

1,415,719
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 25 Aug 2026

% Shorted

0.00% 0.00
vs 0.00% prior report

Most Shorted Rank

598th
of 711 shorted ASX stocks

Peak Short

2.88%
Sep 2016

Days to Cover

0.0
at 50d avg vol
Subject
NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Change of Director's Interest Notice - BP

NOX Ann: Change of Director's Interest Notice - PM

NOX Ann: Details of Company Address

NOX Ann: IONIC Trial Abstract Published at ASCO

NOX Ann: Study results show new Sofra drug reduces inflammation

NOX Ann: Innovative Sofra research presented at European event

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Upcoming Expiry of Listed Options (ASX Code NOXO)

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: March 2023 Quarterly Activities Report and Appendix 4C

NOX Ann: Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs

NOX Ann: Noxopharm Announces Novel mRNA Vaccine Enhancer

NOX Ann: Appendix 4D and Half Year 2023 Financial Report

NOX Ann: Noxopharm to Present Sofra Study at LUPUS 2023 Conference

NOX Ann: December 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: DARRT-2 Trial Efficacy Phase to Commence

NOX Ann: NOX Pipeline Boosted by $1.5M Grant to Hudson Institute

NOX Ann: Change of Director's Interest Notice - FB

NOX Ann: Notification of cessation of securities - NOX

NOX Ann: Federal Innovation Connections Grant Awarded

NOX Ann: IONIC Trial Progresses as Veyonda Passes Safety Milestone

NOX Ann: Notification of cessation of securities - NOX

NOX Ann: Constitution

NOX Ann: Results of Meeting

NOX Ann: Noxopharm 2022 AGM Corporate Presentation

NOX Ann: Noxopharm AGM 2022 Chair's Address

NOX Ann: CEP-2 Safety Milestone Shows Veyonda Progress

NOX Ann: Noxopharm Enhances Cash Position via R&D Rebate

NOX Ann: Change in substantial holding

NOX Ann: September 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: 2022 AGM Notice of Meeting and Proxy

NOX Ann: 2022 AGM Letter to Shareholders and Proxy

NOX Ann: Unlisted Options Expiring on 21 November 2022

NOX Ann: Noxopharm 2022 Annual Report

NOX Ann: Final Director's Interest Notice - GK

NOX Ann: Resignation of Dr Graham Kelly as Non-Executive Director

NOX Ann: Novel Dual-cell Therapy Results in Pancreatic Cancer

NOX Ann: Response to ASX Price Query (Correction to ASX Ticker)

NOX Ann: Response to ASX Price Query

NOX Ann: Appendix 4E and Audited Financial Statements

NOX Ann: Appendix 4G and Corporate Governance Statement

NOX Ann: Noxopharm & UNSW Pancreatic Cancer Research at US Conference

NOX Ann: CEP-2 Trial Passes Safety Milestone

NOX Ann: DARRT-2 Trial Safety Milestone and European Site Activated

NOX Ann: June 2022 Quarterly Activities Report and Appendix 4C

NOX Ann: Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial

NOX Ann: $1.45M Grant to Hudson Institute for Noxopharm Collaboration

NOX Ann: HIMR Collaboration Secures mRNA Vic Acceleration Fund Grant

If you were already registered, log in here.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX
S88
MAV
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS
MBM